Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Strata Critical Medical (SRTAW) EBITDA Margin (2020 - 2025)

Historic EBITDA Margin for Strata Critical Medical (SRTAW) over the last 6 years, with Q3 2025 value amounting to 11.4%.

  • Strata Critical Medical's EBITDA Margin rose 82600.0% to 11.4% in Q3 2025 from the same period last year, while for Sep 2025 it was 11.34%, marking a year-over-year increase of 205500.0%. This contributed to the annual value of 13.64% for FY2024, which is 166100.0% up from last year.
  • Strata Critical Medical's EBITDA Margin amounted to 11.4% in Q3 2025, which was up 82600.0% from 7.0% recorded in Q2 2025.
  • Strata Critical Medical's 5-year EBITDA Margin high stood at 7.0% for Q2 2025, and its period low was 75.05% during Q4 2023.
  • Over the past 5 years, Strata Critical Medical's median EBITDA Margin value was 22.81% (recorded in 2022), while the average stood at 30.78%.
  • As far as peak fluctuations go, Strata Critical Medical's EBITDA Margin crashed by -459600bps in 2021, and later skyrocketed by 625400bps in 2024.
  • Over the past 5 years, Strata Critical Medical's EBITDA Margin (Quarter) stood at 42.8% in 2021, then dropped by -21bps to 51.6% in 2022, then crashed by -45bps to 75.05% in 2023, then skyrocketed by 83bps to 12.52% in 2024, then rose by 9bps to 11.4% in 2025.
  • Its EBITDA Margin was 11.4% in Q3 2025, compared to 7.0% in Q2 2025 and 13.96% in Q1 2025.